Table 1.
Clinical and pathologic characteristics according to the depth of stromal invasion groups
| Variable | Patients (%) | Subcategorization of DSI | P value | ||
|---|---|---|---|---|---|
| Total = 3298 | <full-thickness (n=1998, 60.6%) | full-thickness (n=1106, 33.5%) | > full-thickness (n=194, 5.9%) | ||
| Median age (years) | 47.0 (ranging 19 - 80) | 46.0 (ranging 19 - 79) | 49.0 (ranging 20 - 78) | 52.0 (ranging 20 - 80) | < 0.001 |
| Histologic type | 0.817 | ||||
| Squamous carcinoma | 2936 (89.0%) | 1783 (89.2%) | 984 (89.0%) | 169 (87.1%) | |
| Adenocarcinoma | 245 (7.4%) | 142 (7.1%) | 85 (7.7%) | 18 (9.3%) | |
| Adenosquamous carcinoma | 117 (3.5%) | 73 (3.7%) | 37 (3.3%) | 7 (3.6%) | |
| FIGO stage (2009) | < 0.001 | ||||
| IB1 | 1165 (35.3%) | 881 (44.1%) | 258 (23.3%) | 26 (13.4%) | |
| IB2 | 308 (9.3%) | 193 (9.7%) | 100 (9.0%) | 15 (7.7%) | |
| IIA1 | 1252 (38.0%) | 680 (34.0%) | 468 (42.3%) | 104 (53.6%) | |
| IIA2 | 573 (17.4%) | 244 (12.2%) | 280 (25.3%) | 49 (25.3%) | |
| Menopause status | < 0.001 | ||||
| Menopause | 1136 (34.4%) | 616 (30.8%) | 429 (38.8%) | 91 (46.9%) | |
| Premenopause | 2162 (65.6%) | 1382 (69.2%) | 677 (61.2%) | 103 (53.1%) | |
| Parity | 0.115 | ||||
| Yes | 3150 (95.5%) | 1901 (95.1%) | 1067 (96.5%) | 182 (93.8%) | |
| No | 148 (4.5%) | 97 (4.9%) | 39 (3.5%) | 12 (6.2%) | |
| Mean tumor diameter (cm) | 3.9 (ranging 0.4 - 12.0) | 3.7 (ranging 0.4 - 12.0) | 4.3 (ranging 1.0 - 11.0) | 4.3 (ranging 1.1 - 11.0) | < 0.001 |
| Lymphovascular space invasion | < 0.001 | ||||
| Yes | 1473 (44.7%) | 761 (38.1%) | 578 (52.3%) | 134 (69.1%) | |
| No | 1825 (55.3%) | 1237 (61.9%) | 528 (47.7%) | 60 (30.9%) | |
| Lymph node metastasis | < 0.001 | ||||
| Yes | 1060 (33.2%) | 469 (24.5%) | 465 (42.8%) | 126 (66.3%) | |
| Only Pelvic | 962 | 440 | 418 | 104 | |
| Only Para-aortic | 4 | 3 | 1 | 0 | |
| Pelvic + Para-aortic | 71 | 22 | 33 | 16 | |
| No | 2128 (66.8%) | 1443 (75.5%) | 621 (57.2%) | 64 (33.7%) | |
| Parametrial involvement | < 0.001 | ||||
| Yes | 244 (7.4%) | 91 (4.6%) | 105 (9.5%) | 48 (24.7%) | |
| No | 3054 (92.6%) | 1907 (95.4%) | 1001 (90.5%) | 146 (75.3%) | |
| Vaginal margin invasion | < 0.001 | ||||
| Yes | 106 (3.2%) | 48 (2.4%) | 43 (3.9%) | 15 (7.7%) | |
| No | 3192 (96.8%) | 1950 (97.6%) | 1063 (96.1%) | 179 (92.3%) | |
| Recurrent region | 0.029 | ||||
| Only pelvic | 187 (31.0%) | 99 (36.5%) | 69 (27.1%) | 19 (24.7%) | |
| Only extrapelvic | 346 (57.4%) | 142 (52.4%) | 160 (62.7%) | 44 (57.1%) | |
| Pelvic + extrapelvic | 70 (11.6%) | 30 (11.1%) | 26 (10.2%) | 14 (18.2%) | |
| Adjuvant radiotherapy | < 0.001 | ||||
| Yes | 2334 (70.8%) | 1320 (66.1%) | 860 (77.8%) | 154 (79.4%) | |
| No | 340 (10.3%) | 231 (11.6%) | 100 (9.0%) | 9 (4.6%) | |
| Unknown | 624 (18.9%) | 447 (22.4%) | 146 (13.2%) | 31 (16.0%) | |
| Adjuvant chemotherapy | < 0.001 | ||||
| Yes | 1137 (34.5%) | 632 (31.6%) | 421 (38.1%) | 84 (43.3%) | |
| No | 1399 (42.4%) | 843 (42.2%) | 492 (44.5%) | 64 (33.0%) | |
| Unknown | 762 (23.1%) | 523 (26.2%) | 193 (17.5%) | 46 (23.7%) | |